Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Bristol-Myers Squibb (NY: BMY)
59.97 USD  -0.35 (-0.58%)
Streaming Delayed Price  /  Updated: 11:53 AM EDT, May 27, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 5,807,605
Open 60.00
Bid (Size) 59.96 (8)
Ask (Size) 59.97 (2)
Prev. Close 60.32
Today's Range 59.11 - 60.19
52wk Range 42.48 - 68.34
Shares Outstanding 1,634,538,458
Dividend Yield 2.67%
Performance
YTD
-5.32%
-5.32%
1 Month
-4.14%
-4.14%
3 Month
-3.49%
-3.49%
6 Month
+5.58%
+5.58%
1 Year
+30.77%
+30.77%
Top News
More News
Biotech Brief: Global Glioblastoma Multiforme Drug Market Could Exceed $1.4 Billion By 2025
category Featured News
from FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Brief: Global Glioblastoma Multiforme Drug Market Could Exceed $1.4 Billion by 2025
Financialnewsmedia.com News Commentary Read More
from PR Newswire
More News
Read More
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT
from GlobeNewswire News Releases
Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity
from PR Newswire
Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
from Business Wire News Releases
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
from Business Wire News Releases
Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb
from Business Wire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT
from GlobeNewswire News Releases
Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential
category Analyst Ratings , Trading Ideas , Biotech , and 10 more.
from Benzinga
European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486
from Business Wire News Releases
This is the time for active managers to shine. How—and what—are they doing?
category UNH , NOW , PYPL , and 16 more.
from MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.